| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/11/2005 | US20050176702 1,8-Annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
| 08/11/2005 | US20050176701 Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| 08/11/2005 | US20050176700 (2-methoxyphenyl)acetic acid-7-{4-[3-(2-methoxybenzyloxy)-propoxy]phenyl}-3-(2-thiophen-2-ylacetyl)-3,9-diazabicyclo[3.3.1]non-6-en-6-yl-methyl ester; metabolically stable, orally bioavailable and sufficiently soluble; industrial scale; non-peptidic nature, low molecular weight |
| 08/11/2005 | US20050176698 Neuropeptide Y antagonists |
| 08/11/2005 | US20050176697 crystal of 3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-7 beta -[2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-cephem-4-carboxylate with acetic acid and water, crystals; anti-Methicillin Resistant Staphylococcus aureus agent; storage stability, high purity |
| 08/11/2005 | US20050176696 Synergistic anit-cancer compounds |
| 08/11/2005 | US20050176694 steroids such as (11 beta )-11-17-dihydroxy-21-[N-acetyl-S-(4-nitroxybutyroyl) cisteinyloxy]pregne-1,4-diene-3,20-dione having antiinflammatory, immunodepressive and angiostatic activity |
| 08/11/2005 | US20050176693 Controlling times of dosage ; administerin gby mouth serotonin reuptake inhibitor |
| 08/11/2005 | US20050176692 Oral androgen therapy using modulators of testosterone bioavailability |
| 08/11/2005 | US20050176691 Combination therapy for the treatment of estrogen-sensitive disease |
| 08/11/2005 | US20050176690 Administering purine nucleoside for treatment of arthritis inflammation |
| 08/11/2005 | US20050176688 Halocombstatins and methods of synthesis thereof |
| 08/11/2005 | US20050176687 Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| 08/11/2005 | US20050176686 for HDACs (1-10) or Silent Information Regulator (SIR2) protein family; 3-Cyclopentyl-N-hydroxy-propionamide; antiproliferative agent for tumor cells and other abnormal gene expression |
| 08/11/2005 | US20050176685 Administering bisphosphonate compounds such as ibandronate, minodronate, pamidronate, risedronate, zoledronate, and alendronate; osteoporosis |
| 08/11/2005 | US20050176684 5-(4-Bromo-3-aminophenyl)-2-furanphosphonic acid; fructose-1,6-biphosphatase inhibitor; diabetes type 1 and 2, glycogen storage diseases, cardiovascular diseases with increased insulin levels, atherosclerosis; in vitro, in vivo; |
| 08/11/2005 | US20050176683 Hexa-/Tetra-hydro-pyrrolo[1,2-a]imidazole-2,5-dione derivatives; solid phase synthesis |
| 08/11/2005 | US20050176681 Immunomodulators; side effect reduction; non-Hodgkin's lymphoma, myelogenous leukemia, amyloidosis, and cancer of ovaries, pancreas, kidneys |
| 08/11/2005 | US20050176680 Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| 08/11/2005 | US20050176679 Process for the preparation of free flowing pulverized adsorbates of tibolone |
| 08/11/2005 | US20050176678 Compounds and method for coating surfaces in a haemocompatibe manner |
| 08/11/2005 | US20050176677 Pectic isolate comprising apiose motif from plant of Lemnaceae family; allergies; inflammation |
| 08/11/2005 | US20050176676 Administering choline cytidine 5-pyrophosphate which raises levels of uridine or uridine phosphate; improving memory, learning, cognition, synaptic transmission, synthesis/release of neurotransmitters, and increasing brain phospholipid levels; Alzheimer's disease |
| 08/11/2005 | US20050176675 Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
| 08/11/2005 | US20050176674 Administering sulfur containing amino acid and manganese |
| 08/11/2005 | US20050176673 guanin-9-yl, adenin-9-yl, 2,6-diaminopurin-9-yl, 2-aminopurin-9-yl or their 1-deaza, 3-deaza, or 8-aza compounds, or cytosin-1-yl - ethoxymethanephosphonic acid derivatives, used to treat osteoporosis and other disorders of bone metabolism, cancer, or viral infections |
| 08/11/2005 | US20050176672 Use of cationic lipids to generate anti-tumor immunity |
| 08/11/2005 | US20050176669 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 08/11/2005 | US20050176662 Administering an agent that modulates the expression or activity of an Age-related macular degeneration (AMDP)-related or phagocytosis-related gene for delaying or reversing a retinal or choridal degenerative disease |
| 08/11/2005 | US20050176661 Antiviral oligonucleotides |
| 08/11/2005 | US20050176659 Polypeptide contributing to regulating the metabolism of triglycerides; obesity as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstone, cancers of the reproductive organs |
| 08/11/2005 | US20050176658 Method of using protease inhibitors for the treatment of liposarcomas |
| 08/11/2005 | US20050176657 Anthelmintic oral homogeneous veterinary pastes |
| 08/11/2005 | US20050176655 Novel macrolide derivatives havaing effect of potentiating antifungal activity |
| 08/11/2005 | US20050176654 Composition for regulating bone metabolism |
| 08/11/2005 | US20050176653 Cultivating a Amycolatopsis orientalis strain under aerobic conditions, chemically modifying the product; antibiotics; anticarcinogenic agent, antiinflammatory agent |
| 08/11/2005 | US20050176652 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 08/11/2005 | US20050176651 Peptide boronic acids useful in making salts thereof |
| 08/11/2005 | US20050176650 ethylenediaminetetraacetic acid (EDTA) or salt as first stabilizer, and monothioglycerol (MTG) or glutathione as second stabilizer; psychosis, agitation, pain, migraine headache, nausea, vomiting, itching, hypertension, benign prostatic hypertrophy, excess gastrointestinal secretions, sleeplessness |
| 08/11/2005 | US20050176648 oligopeptide including enantiomers, stereoisomers and tautomers, used as hepatitis c protease enzyme inhibitors for prophylaxis or prevention of viral diseases |
| 08/11/2005 | US20050176647 Having an alkylation site via a vinyl linker at the end of a pyrrole-imidazole polyamide; inhibits the expression of a specific gene; high anti-cancer activity |
| 08/11/2005 | US20050176642 Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric GP120 |
| 08/11/2005 | US20050176639 Use of osteopontin for the treatment and/or prevention of neurologic diseases |
| 08/11/2005 | US20050176633 low-molecular weight compounds, peptides and proteins, particularly antibodies or antibody fragments; drug screening; increased G-protein mediated signal transduction |
| 08/11/2005 | US20050176632 Angiogenesis inhibitors |
| 08/11/2005 | US20050176630 Modification of feeding behavior |
| 08/11/2005 | US20050176626 modulating production of neurons and/or oligodendrocytes from neural progenitor cells of human white matter and to a method of treating a subject for a condition modulated by underproduction of oligodendrocytes from human white matter, sterol inhibitors |
| 08/11/2005 | US20050176624 Organometallic complexes as singlet oxygen sensitizers |
| 08/11/2005 | US20050176622 secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of DP IV |
| 08/11/2005 | US20050176620 Crosslinked compounds and methods of making and using thereof |
| 08/11/2005 | US20050176619 N-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl]formamide, or a pharmaceutically acceptable acid-addition salt thereof, and to the method of use thereof in the treatment of tumors and cancers. |
| 08/11/2005 | US20050176094 Polypeptide having immunomodulatory activity, antiviral activity, and antitumor activity; polynucleotides, expression vectors , probes and antibodies; predicting responsiveness to treatment with interferon- alpha and other interferons which act at the Type 1 interferon receptor |
| 08/11/2005 | US20050176087 Diagnosis and treatment of human kidney diseases |
| 08/11/2005 | US20050176074 Rapid screening for identifying acylfulvenes and analogs thereof with improved chemotherapeutic properties; oxidoreductases |
| 08/11/2005 | US20050176057 Using single nuclelotide polymorphism in norepinephrine transport protein gene sequences as prognostic/diagnostic tool in treatment and prevention of depression and biopolar disorders; antidepressants; psychotropics |
| 08/11/2005 | US20050176018 Increased nuclease resistance; gene expression inhibition |
| 08/11/2005 | US20050176013 Identifying modulators of 3'-phosphoadenosine 5'-phosphosulfate synthase 1(PAPPS-1) activity; antitumor agents; tumor diagnostics |
| 08/11/2005 | US20050175763 Phosphatidyl serine, phosphatidyl choline and similar compounds; food for tube feeding; health-giving, performance-enhancing or disease-preventing (eg diabetes) |
| 08/11/2005 | US20050175748 Antimicrobial envelopes |
| 08/11/2005 | US20050175722 Extracts of Tribulus terrestris, Epimedium koreanum, Cinnamon cassia, arginine, and carrier/excipient |
| 08/11/2005 | US20050175718 Anti-allergy composition and related method |
| 08/11/2005 | US20050175715 Cellular depolarization and regulation of matrix metalloproteinases |
| 08/11/2005 | US20050175706 Sustained release oral formulations |
| 08/11/2005 | US20050175704 Polyacrylamide hydrogel as a soft tissue filler endoprosthesis |
| 08/11/2005 | US20050175703 Polymer compositions and methods for their use |
| 08/11/2005 | US20050175698 Treating depression and reducing gastrointestinal side-effects; sustained release |
| 08/11/2005 | US20050175697 For use with low soluble/low dissolution rate pharmaceuticals |
| 08/11/2005 | US20050175696 Granule substrate comprising a solubilizing agent and/or a low solubility therapeutic drug, and a granule coating of a hydrophilic polymer such as methyl cellulose; oral dosage form of topiramate, comprising a tablet core and an osmotic delivery system |
| 08/11/2005 | US20050175695 exhibit biphasic plasma profile with a first plasma concentration peak level within within 14 hours of ingestion and a second plasma concentration peak level within 5-10 hours after ingestion; treats hypertension, congestive heart failure, atherosclerosis, and angina |
| 08/11/2005 | US20050175694 Long acting compositions comprising zidovudine and lamivudine |
| 08/11/2005 | US20050175692 Pharmaceutical formulation comprising melatonin |
| 08/11/2005 | US20050175691 Pramipexole once-daily dosage form |
| 08/11/2005 | US20050175690 Novel drug compositions and dosage forms |
| 08/11/2005 | US20050175688 Fibrotic condition with associated chronic pain such as cirrhosis of the liver, atherosclerosis, dermatomyositis, progressive systemic sclerosis, pulmonary fibrosis, connective tissue diseases, adhesions and endometriosis |
| 08/11/2005 | US20050175683 Preparation of lipid particles |
| 08/11/2005 | US20050175682 Polyethyleneglycol-modified lipid compounds and uses thereof |
| 08/11/2005 | US20050175679 Controlled release formulations |
| 08/11/2005 | US20050175678 Device for the transdermal administration of a rotigotine base |
| 08/11/2005 | US20050175676 Patch |
| 08/11/2005 | US20050175674 Method of lowering Glycaemic Index of foods |
| 08/11/2005 | US20050175669 Highly lubricious hydrophilic coating utilizing dendrimers |
| 08/11/2005 | US20050175668 Lapachone delivery systems, compositions and uses related thereto |
| 08/11/2005 | US20050175667 Use of endothelin antagonists to prevent restenosis |
| 08/11/2005 | US20050175665 In combination with antiscarring, antifibrotic, and antiinflammatory agents for preventing surgical adhesions, and cartilage loss; hypertrophic scars, keloids, arthritis, vascular disease; injection or topical administration |
| 08/11/2005 | US20050175657 An injectable mixture of a bulking agent and a fibrosing agent chosen from silkworm silk, spider silk, talc, chitosan, polylysine, fibronectin, bleomycin or connective tissue growth factors; increased fibrosis between implant and host tissue |
| 08/11/2005 | US20050175647 Compositions for topical application having androgenic actions |
| 08/11/2005 | US20050175644 Preparation for oxidation-sensitive compounds and method for making same |
| 08/11/2005 | US20050175642 Stable loratadine spill resistant formulation |
| 08/11/2005 | US20050175641 Homogenous liquid blend of hydrophilic polyvinyl alcohol, hydroxypropylmethyl cellulose, hydroxypropyl cellulose , polyvinyl pyrollidone, carbomer, maleic anhydride-methyl vinyl ether decadiene cross polymer and/or hydroxypropylguar; and hydrophobic ethyl cellulose; anti-onychomycoses agents; acne |
| 08/11/2005 | US20050175640 Cyclodextrin and adrenocortical steroid dissolved in aqueous solution; dextran or pullulan; mixture with xyloglucan, trehalose, laminaran, pectin, and krestin; grape sugar, mutan, lentinan, sodium chloride, and/or potassium chloride; side effect reduction; psoriasis, atopic diseases |
| 08/11/2005 | US20050175639 Methods |
| 08/11/2005 | US20050175637 Methods for enhancing wound healing |
| 08/11/2005 | US20050175623 Plant extracts from such as quillaja saponaria molina; potentiators and chemotherapeautics |
| 08/11/2005 | US20050175620 Multivalent platform molecules comprising high molecular weight polyethylene oxide |
| 08/11/2005 | US20050175617 Tie-2 ligands, methods of making and uses thereof |
| 08/11/2005 | US20050175613 Compositions and methods for treating hyperimmune response in the eye |
| 08/11/2005 | US20050175585 Combination therapies using vitamin B12 and interferon for treatment of viral proliferative and inflammatory disesases |
| 08/11/2005 | US20050175584 Functionalized colloidal metal compositions and methods |
| 08/11/2005 | US20050175583 Making vector compositions that mimic the functionality of components of the immune system especially antigen-presenting cell (APC) element of the immune synapse; vaccination |
| 08/11/2005 | US20050175580 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |